Senate HELP Committee ready to pause MU

To the great relief of many who have called for a pause on the federal Meaningful Use program, the Senate Health Education Labor & Pensions (HELP) Committee announced today it will ask the Department of Health and Human Services (HHS) to delay Stage 3. 

Committee Chairman Lamar Alexander (R-Tenn.) said that will be one of several recommendations the HELP committee will make to the Obama administration. The committee held several hearings in recent months to learn more about the challenges clinicians face when using EHRs and other information technology in healthcare. Many testified about the cost and inefficiency of EHRs as well as information blocking practices of numerous stakeholders.

The directives are intentionally being drafted as regulations that can be implemented by HHS Secretary Sylvia Matthews Burwell via rule-making versus legislation for quicker adoption. 

“We want to keep going forward [with the adoption of EHRs], no one wants to turn back,” Alexander said.

"Meaningful Use Stages 1 and 2 created an important foundation," said John Halamka, MD, MS, CIO of Partners HealthCare in Boston. "Only now is the private sector catching up from the backlog of deferred work. At the same time, the Argonaut Project is accelerating interoperability. A delay in MU Stage 3 would actually improve adoption and innovation." 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.